Investor's Business Daily on MSN
Incyte sees composite rating move up to 96
Incyte saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before.
Investor's Business Daily on MSN
Travere Therapeutics sees its composite rating rise to 97
Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results